oral semaglutide novo nordisk says works in diabetic kids Company of the year 2023:

Eli Lilly CEO David Ricks announces details of the Medicare GLP-1 bridge program, offering weight loss medications like Fondeo and Zepbound for $50 per month to 20 million eligible Medicare Part D patients starting July 1.

Two announcements this week, on opposite ends of healthcare: Queue raised money to build autonomous robotic pharmacies

Learn more: read our full guide to microdosing tirzepatide and the GLP-1 microdosing chart

However, staying attuned to systemic health trends is equally critical, especially with the rise of GLP-1 receptor agonists (like semaglutide and liraglutide) in managing diabetes and obesity.